On May 30, Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 while keeping her Buy rating on the PPBT stock. The change comes ...
Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. Unlock your all-in-one trading dashboard with ...
Purple Biotech Ltd. Sponsored ADR (PPBT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Hosted on MSN
Purple Biotech Unveils Promising Cancer Treatment Developments in September 2025 Update
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Purple Biotech ( (PPBT)) has issued an ...
Purple Biotech ( (PPBT)) has shared an update. On December 15, 2025, Purple Biotech Ltd. held an Extraordinary General Meeting of Shareholders at its headquarters in Rehovot, Israel. During the ...
Purple Biotech Ltd. ADR Annual cash flow by MarketWatch. View PPBT net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback